A three months phase IIb study of MP1032 with higher doses in patients with moderate-to-severe chronic plaque psoriasis
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2018
At a glance
- Drugs MP 1032 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Sponsors MetrioPharm
- 11 Dec 2018 According to a MetrioPharm media release, the company expects the results of this study in mid-2019.
- 07 Mar 2018 Status changed from planning to recruiting, according to a MetrioPharm media release.
- 06 Mar 2018 According to a MetrioPharm media release, the company announces first dosing of first patient in this study.